Not applicableStudy completedNCT04760990
What this trial is testing
Assess the Potential Impact of Disease Modifying Therapies on COVID-19 Outcomes and the Antibody Response Following an Infection With SARS-CoV-2 in Patients With Multiple Sclerosis Within the Swiss Multiple Sclerosis Cohort.
Who this might be right for
Multiple SclerosisCOVID-19 (Severe Coronavirus Disease 2019)
University Hospital, Basel, Switzerland 1,181